trial · primary record
nab-paclitaxel in combination with gemcitabine + cisplatin
Unresectable Biliary Tract Cancer
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 45 |
| Primary completion | 2026-12 |
| Primary endpoint | Overall response rates |
| Registry ID | NCT02632305 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:38.810Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02632305
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.